Share this article
Share this article
PLYMOUTH MEETING, Pa., April 23, 2021 /PRNewswire/ INOVIO (NASDAQ:INO), a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, today announced that it is planning for a predominantly ex-U.S. Phase 3 trial for its COVID-19 vaccine candidate, INO-4800. Given the increasing availability of vaccines authorized for emergency use, the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) in coordination with the Office of the Assistant Secretary of Defense for Health Affairs (OASD(HA)) and the Defense Health Agency (DHA), will discontinue funding for the Phase 3 segment of the INNOVATE trial, while continuing to fund the completion of the ongoing Phase 2 segment. In correspondence, JPEO informed INOVIO: The decision results from the changing environment of
Inclusivity is on the mind of Gainesville businesses this week, as the chamber of commerce launches a new initiative to advance equitable economic development and a large Gainesville-based employer announces new health care coverage aimed at helping couples of any orientation start families and provide care for gender affirmation.
Here’s a look at this week’s business news:
Chamber launches Inclusive Gainesville initiative
The Greater Gainesville Chamber of Commerce last week launched Inclusive Gainesville, a community-wide approach to equitable economic development and inclusion.
The initiative will focus on two core areas workforce development and supplier diversity.
Local partners launching Inclusive Gainesville are Charles Perry Partners Inc., Infotech, the InterMed Group, North Florida Regional Medical Center, Oelrich Construction, Ology Bioservices and Porter Brown Associates.
Apr 21, 2021 7:10am
Evotec s U.S. subsidiary Just has won cash from the U.S. Department of Defense and the Bill & Melinda Gates Foundation to work on COVID-fighting monoclonal antibodies. ( Flag of France, Undated (CC BY 2.0) by nathanh100)
A little over a year after Evotec s U.S. subsidiary started work on its biologics facility of the future in Washington, the German biotech-CRO hybrid has unveiled plans to stand up a sister facility in France.
Evotec has kicked off construction on a new biologics factory in Toulouse dubbed J.POD 2 EU, the company said Tuesday. The French government, investment bank Bpifrance, the city of Toulouse and more will chip in up to €50 million ($60.18 million) for the project. Evotec plans to invest around €150 million ($180.53 million).
The global vaccine contract manufacturing market by revenue is expected to grow at a CAGR of approx. 13% during the period 2020–2026 In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Vaccine Contract Manufacturing Market Report. The global vaccine contract manufacturing market by revenue is expected to grow at a CAGR of approx.
April 16, 2021 09:32 ET | Source: ReportLinker ReportLinker Lyon, FRANCE
New York, April 16, 2021 (GLOBE NEWSWIRE) Reportlinker.com announces the release of the report Vaccine Contract Manufacturing Market - Global Outlook and Forecast 2021-2026 - https://www.reportlinker.com/p06063357/?utm source=GNW 13% during the period 2020–2026.
The global vaccine contract manufacturing market has experienced radical transformations after the outbreak of the COVID-19 pandemic, which has been a massive health catastrophe. Vaccine CMOs have gained s
One Billion Doses On Day One : Vaccine Company Claims World-Changing Innovation forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.